Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects
Authors:
- Ali A. RabaanARAli A. Rabaan
- Muhammed A. BakhrebahMBMuhammed A. Bakhrebah
- Ranjan K. MohapatraRanjan K. Mohapatra
- Ramadan Abdelmoez FarahatRamadan Abdelmoez Farahat
- Manish DhawanManish Dhawan
- Sara AlwarthanSASara Alwarthan
- Mohammed AljeldahMAMohammed Aljeldah
- Basim R. Al ShammariBSBasim R. Al Shammari
- Amal H. Al-NajjarAAAmal H. Al-Najjar
- Mona A. AlhusayyenMAMona A. Alhusayyen
- Ghadeer H. Al-AbsiGAGhadeer H. Al-Absi
- Yahya AldawoodYAYahya Aldawood
Open Access
Abstract
Leishmaniasis is a zoonotic disease transmitted in humans by the bite of Leishmania-infected phlebotomine sandflies. Each year approximately 58,500 cases of leishmaniasis are diagnosed across the globe, with a mortality rate of nearly seven percent. There are over 20 parasitic strains of Leishmania which are known to cause distinct types of leishmaniasis and pose an endemic threat to humans worldwide. Therefore, it is crucial to develop potential medications and vaccines to combat leishmaniasis. However, the task of developing therapeutic solutions is challenging due to Leishmania’s digenetic lifecycle. The challenge is further intensified by cases of resistance against the available drugs. Owing to these challenges, the conventional drug development regimen is further limited by target discovery and ligand suitability for the targets. On the other hand, as an added advantage, the emergence of omics-based tools, such as high-end proteomics, transcriptomics and genomics, has hastened the pace of target discovery and target-based drug development. It is now becoming apparent that multi-omics convergence and an inter-connected systems approach is less time-consuming and more cost-effective for any drug-development process. This comprehensive review is an attempt to summarize the current knowledge on the muti-omics approach in drug development against leishmaniasis. In particular, it elaborates the potential target identification from secreted proteins in various stages of Leishmania infection and also illustrates the convergence of transcriptomic and genomic data towards the collective goal of drug discovery. This review also provides an understanding of the potential parasite’s drug targets and drug resistance characteristics of the parasite, which can be used in designing effective and specific therapeutics.Keywords
This publication has 96 references indexed in Scilit:
- The Cell Biology of Leishmania: How to Teach Using AnimationsPLOS Pathogens, 2013
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trialTrials, 2011
- Diagnosis of visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2011
- Protein network prediction and topological analysis in Leishmania major as a tool for drug target selectionBMC Bioinformatics, 2010
- Quantitative proteomics approach for identifying protein–drug interactions in complex mixtures using protein stability measurementsProceedings of the National Academy of Sciences, 2010
- Pentavalent Antimonials: New Perspectives for Old DrugsMolecules, 2009
- In Vivo Imaging Reveals an Essential Role for Neutrophils in Leishmaniasis Transmitted by Sand FliesScience, 2008
- Proteomic analysis of the secretome of Leishmania donovaniGenome Biology, 2008
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970